Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW, Manro JR, Shih C, Stewart JA, Stewart TR, Stout SL, Uhlik MT, Um SL, Wang Y, Wu W, Yan L, Yang WJ, Zhong B, Walgren RA. Yan SB, et al. Among authors: zhong b. Invest New Drugs. 2013 Aug;31(4):833-44. doi: 10.1007/s10637-012-9912-9. Epub 2012 Dec 29. Invest New Drugs. 2013. PMID: 23275061 Free PMC article. Clinical Trial.
Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P, Dong J, Zhong B, Zhang D, Yuan H, Jin C, Xu X, Li H, Zhou Y, Liang Z, Ji M, Xu T, Song G, Zhang L, Chen G, Meng X, Sun D, Shih J, Zhang R, Hou G, Wang C, Jin Y, Yang Q. Zhang P, et al. Among authors: zhong b. Bioorg Med Chem Lett. 2016 Apr 15;26(8):1910-8. doi: 10.1016/j.bmcl.2016.03.017. Epub 2016 Mar 7. Bioorg Med Chem Lett. 2016. PMID: 26979157
Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P, Dong J, Zhong B, Zhang D, Jin C, Meng X, Sun D, Xu X, Zhou Y, Liang Z, Ji M, Li H, Xu T, Song G, Zhang L, Chen G, Yuan H, Shih J, Zhang R, Hou G, Jin Y, Yang Q. Zhang P, et al. Among authors: zhong b. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3738-43. doi: 10.1016/j.bmcl.2015.06.021. Epub 2015 Jun 16. Bioorg Med Chem Lett. 2015. PMID: 26130408
Validation Status of Electronic Sphygmomanometers in China: A National Survey.
Zhang X, Xu Z, Yao Y, Zheng H, Wu J, Hu J, Wu S, Lyu Q, Liu Y, Wu M, Chen L, Xu L, Zhou H, Duan P, Dai J, Ding H, Wang S, Zhao Y, Hu J, Zhu L, Hai R, Zhong B, Zhu H, Li K, Lu Y, Tang S, Li X, Zhang Y, Chen Z, Wang T, Li M, Liu F, Liu C, Yang X, Dong L, Ma J, Gao P, Xie W, Wu Y. Zhang X, et al. Among authors: zhong b. Hypertension. 2025 Jan 14. doi: 10.1161/HYPERTENSIONAHA.124.24203. Online ahead of print. Hypertension. 2025. PMID: 39807594
1,967 results